Compare Adaptive Biotechnologies Corp (ADPT) vs C3.ai Inc (AI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs C3.ai Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.47 (market cap $4.04B), while C3.ai Inc trades at $10.39 (market cap $1.65B). The key difference: Adaptive Biotechnologies Corp is far larger — about 2.4× C3.ai Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | AI | |
|---|---|---|
Market Cap | $4.04B | $1.65B |
Sector | Health | Technology |
52-Week High | $25.45 | $19.66 |
52-Week Low | $12.30 | $7.76 |
Enterprise Value | $4.10B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
C3.ai (AI) trades at $10.40, up 1.76% with a bullish technical signal despite negative profitability metrics. The company reported Q1 2026 earnings beat but maintains negative net margins of -187.95%. Recent news highlights C3.ai being named a leader in AI platforms by Forrester Research, while technical indicators show RSI levels near 90 suggesting overbought conditions.
The stock faces significant fundamental challenges with persistent losses and negative cash flow, though revenue growth and leadership positioning in enterprise AI provide long-term potential. Analyst consensus is mixed with a $10.20 price target, indicating cautious optimism amid execution risks and competitive pressures in the AI software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →
